Condition: Acute on Chronic Liver Failure (ACLF) · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Spontaneous Observational Prospective Multicenter study of all patients admitted to Intensive Care with a diagnosis of Acute on Chronic Liver Failure (ACLF) of grade ≥ 2 for which the use of the system will be authorized extracorporeal purification with DM CYTOSORB. The hypothesis underlying the study is to evaluate whether the modulation of bilirubin and other toxic molecules and mediators, obtainable through the use of systems extracorporeal purification (specifically DM CYTOSORB), may have an impacton the degree of organ failure in patients with ACLF. The study proposes the compilation of a structured and shared data collection with other Italian Intensive Care Centers which include patients suffering from ACLF (multicenter study) of clinical and laboratory parameters, which are part of normal clinical practice.
This description comes directly from the study's public registry record.
Antonio Siniscalchi, MD · +393383244708 · antonio.siniscalchi@aosp.bo.it
Cristiana Laici, MD · +393471960155 · cristiana.laici@aosp.bo.it
Always discuss trial participation with your own doctor first.
| Azienda Ospedaliero-Universitaria Ospedale Riuniti Umberto I - GM Lancisi - G Salesi, Ancona | Ancona, Ancona, Italy | Recruiting |
| IRCCS Azienda Ospedaliero Universitaria di Bologna | Bologna, Bologna, Italy | Recruiting |
| Anestesia e Rianimazione 2, Ospedale Niguarda Ca' Granda, Milano | Milan, Milano, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06837766